Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up periods reaching approximately one year. The trial design included both an open-label extension and a randomized withdrawal phase, allowing assessment of both sustained benefit and what happens when treatment stops. Results from this large, well-controlled study contribute meaningful clinical evidence on whether a standardized cannabis-based product can serve as a safer alternative to current pharmacologic options for this condition.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a significant clinical gap by providing rigorous evidence for cannabis-based treatment in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and carry abuse potential. The large sample size (820 participants) and double-blind design with 12-week treatment duration and 6-month extension offer robust data on both efficacy and safety profiles necessary for clinical decision-making and potential regulatory approval. Given the opioid crisis and inadequate pain relief from conventional therapies, establishing an evidence-based botanical alternative could substantially impact treatment algorithms and reduce patient morbidity in this high-burden population.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial of a full-spectrum cannabis extract (VER-01) for chronic low back pain enrolled a substantial cohort and represents meaningful progress in the systematic evaluation of cannabis for a condition where conventional pharmacotherapy often falls short, though several practical considerations warrant careful interpretation. The 12-week double-blind period followed by open-label extension is a reasonable design, yet we should note that long-term durability, optimal dosing strategies, and comparative effectiveness against multimodal approaches (physical therapy, psychological interventions) remain incompletely characterized, and individual variation in response to full-spectrum products can be substantial due to cannabinoid ratios and terpene profiles. Real-world efficacy may differ from trial conditions given differences in patient populations, comorbidities affecting pain processing, and concurrent medications that could interact with cannabinoids. For clinicians considering cannabis medicine in CLBP management, this trial provides useful safety and efficacy data, but the decision to recommend should still integrate individualized risk-benefit assessment, discussion